TGF-beta Inhibitors

Transforming Growth Factor beta (TGF-beta) is a multifunctional cytokine and a member of a large family of cytokines that controls many aspects of cellular function, including cell proliferation, differentiation, migration, apoptosis, adhesion, angiogenesis, immunological surveillance and survival.
Related to cell proliferation and tumorigenesis, TGF-beta bears both a tumor-suppressor and a tumor-promotor activity. TGF-beta controls cell growth and motility in part through its regulation of tumor microenvironment and plays a key role in tumor development.
TGF-beta is expressed during development stages, regulating interactions between epithelial and mesenchymal cells, particularly in the lung, kidney, and mammary gland. Aberrantly, inadequate reactivation of the epithelial-mesenchymal transition (EMP) during tumorigenesis is now acknowledged to be a key process in the development of invasive and metastatic tumors.
Under normal conditions, TGF-beta is also a powerful suppressor of mammary epithelial cells (MEC) proliferation and thus an inhibitor of mammary tumo formation. However, aberrant genetic and epigenetic events in tumorigenesis cancel the cytostatic function of TGF-beta, which contributes to tumor progression.
Therapeutics designed to antagonise TGF-beta might be a good strategy to inhibit cancer progression and improve the prognosis and treatment of cancer patients.


By continuing to use the site, you agree to the use of cookies. Continue, scroll or accept. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.